Form 4 for AYTU AYTU BIOPHARMA, INC
Accepted 2022-12-21 00:00:00 ET · period of report 2022-12-19 · accession 0001567619-22-021900 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-21 | 2022-12-19 | AYTU | Disbrow Joshua R. | CEO, Dir | P - Purchase | $0.22 | +112.4K | 1.23M | +10% | +$24.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-19 | P | A | 112,371 | $0.22 | 1,231,877 | D | — | — | (F1) The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.213 to $0.23, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |